British Lung Foundation

miRagen Therapeutics to Present New Promising Data on MRG-201 at ERS 2017

miRagen Therapeutics, a biopharmaceutical company involved in the discovery of RNA-based therapies, will present new preclinical safety and feasibility data for the therapy MRG-201 in the treatment of pulmonary fibrosis at the upcoming European Respiratory Society (ERS) International Congress.


You may also like...